摘要
目的研究克感利咽口服液体内、外抗冠状病毒的作用。方法接种非SARS冠状病毒中华株ZHZ(HK3D3)于人肺K1二倍体细胞(HEL),观察克感利咽口服液体外抗非SARS冠状病毒中华株ZHZ(HK3D3)的作用;以鸡传染性支气管炎病毒(IBV)建立动物体内冠状病毒模型,筛选易感鸡种,诱其发病。以雏鸡的死亡率、死亡保护率及病理变化为指标,观察克感口服液体内抗鸡传染性支气管炎病毒(鸡冠状病毒)的作用。结果体外实验:克感利咽口服液的半数毒性浓度为32g/L,在其最高稀释浓度0.156g/L下,仍可以抑制病毒。体内实验:克感利咽口服液预防及治疗实验的死亡保护率分别为35.1%和26.50%,未见显著性差异。结论克感利咽口服液体内未见抗冠状病毒作用,但能一定程度上改善病毒感染引起的呼吸道症状;体外则有明显的抗非SARS冠状病毒作用,显示了一定的开发前景。
Objective To Study the Kegan Liyan Oral Liquid（KLOL）for counteracting coronavirus in vivo and vitro. Methods HK3D3 was inoculated into HEL cell, and then the effect of KLOL for counteracting non - SARS coronavirus was evaluated; The internal coronavius animal models were established with infective bronchitis virus （IBV）. The susceptible chicken was screened out, infected the chicken to induce morbidity . The mortality, protective rate of mortality and pathogenic changes were observed . Results In - vitro test： The TD50 of KLOL is 32 g/L, and KLOL at MIC being 0. 156 g/L can also inhibit the virus. In - vivo test ： The mortality was 35. 1% and preventive rate 26.50% , the difference was insignificant. Conclusion KLOL exerts no effect on counteracting coronavius in vivo, but it can relieve respiratory symptoms. KLOL has marked in- vitro effects for non- SARS, and its therapeutic mechanism needs further study.
出处
《中药新药与临床药理》
CAS
CSCD
2007年第5期349-353,共5页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
广东省中医药管理局资助项目(203006)
关键词
克感利咽口服液
冠状病毒
体内
体外
Kegan Liyan Oral Liquid
Coronavirus
In vivo
In vitro
作者简介
林吉（1961-），男，副研究员，从事新药开发研究工作。
